Biomarker Consortia: Disease Stratification and Progression

Target ALS is particularly interested in supporting projects that propose the study of:

• Cryptic exons and cryptic exon-related biomarkers
• Biomarkers with utility in ongoing or upcoming therapeutic trials
• Biomarkers for patient population stratification for specific therapeutics (e.g. presence of specific cryptic exons, cognitive involvement, ALS/FTD spectrum)

Funding: $130,000 per lab per year (max. budget per year is $500,000)

Duration: 2+1 years

Research Authority due date: 22.5.24

LOI (required) due date: 29.5.24

Full proposal due date: 21.8.24